Histone Deacetylase Inhibitors and Phenotypical Transformation of Cancer Cells

Histone deacetylase inhibitors (HDIs) are a group of potent epigenetic drugs which have been investigated for their therapeutic potential in various clinical disorders, including hematological malignancies and solid tumors. Currently, several HDIs are already in clinical use and many more are on cli...

Descripción completa

Detalles Bibliográficos
Autores principales: Wawruszak, Anna, Kalafut, Joanna, Okon, Estera, Czapinski, Jakub, Halasa, Marta, Przybyszewska, Alicja, Miziak, Paulina, Okla, Karolina, Rivero-Muller, Adolfo, Stepulak, Andrzej
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6406474/
https://www.ncbi.nlm.nih.gov/pubmed/30691229
http://dx.doi.org/10.3390/cancers11020148

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6406474/
https://www.ncbi.nlm.nih.gov/pubmed/30691229
http://dx.doi.org/10.3390/cancers11020148

Ejemplares similares